America’s insurance industry is currently riveted on the details of an interesting court case from Washington State. That matter centrally spotlights the extension of personal liability in bad-faith litigation.
It immediately makes sense why drug manufacturers would seek coverage from insurers against claims that opioid-linked addictions and resulting harms spiked following their alleged downplaying of known drug risks for users.
Many insurance companies are stuck between that proverbial “rock and a hard place” when it comes to cyberattack claims. Those increasingly issue from commercial policyholders who have generalized risk policies rather than specific cyberattack coverage.
The age-old American maxim “turnabout is fair play” conveys a fairly simple idea, namely this: If you get the chance to do something, fairness dictates that I receive the same opportunity.
“Time is of the essence.”